Horizon Discovery Co-founders Work to be Showcased as Breakthrough in Cancer Research at AACR 2009 »
The work of Horizon Discovery co-founder and Principal Scientific Advisor, Professor Alberto Bardelli showing how KRAS, BRAF, PI3KCA mutations and loss of PTEN expression impairs the response to EGFR-targeted therapies in metastatic colorectal cancer has been selected by the organizers of the American Association of Cancer Research as one of six breakthroughs in cancer research to be spotlighted in a special plenary session at their annual conference to be held in Denver on April 18th to April 22nd. The special session will be held on Monday, April 20, 2009 – 7:45 AM-10:40 AM – Hall A, Colorado Convention Center followed by a press briefing with Medscape on Tuesday, April 21st from 3pm-4pm.